Research graph
References from A novel HIV triple broadly neutralizing antibody (bNAb) combination-based passive immunization of infant rhesus macaques achieves durable protective plasma neutralization levels and mediates anti-viral effector functions. Local targets link to admitted publications; unresolved targets remain external evidence.
Global HIV & AIDS statistics—Fact sheet
2023 · External reference
Time of HIV Diagnosis and Engagement in Prenatal Care Impact Virologic Outcomes of Pregnant Women with HIV.
10.1371/journal.pone.0132262 · 2015 · External reference
Adherence to HIV Antiretroviral Therapy Among Pregnant and Breastfeeding Women, Non-Pregnant Women, and Men in Burkina Faso: Nationwide Analysis 2019–2020.
10.2147/ppa.s354242 · 2022 · External reference
Mother to child transmission of HIV among Zimbabwean women who seroconverted postnatally: prospective cohort study
10.1136/bmj.c6580 · 2010 · External reference
HIV reservoirs as obstacles and opportunities for an HIV cure
10.1038/ni.3152 · 2015 · External reference
Estimated Lifetime HIV-Related Medical Costs in the United States.
10.1097/olq.0000000000001366 · 2021 · External reference
A Review of Long-Term Toxicity of Antiretroviral Treatment Regimens and Implications for an Aging Population.
10.1007/s40121-018-0201-6 · 2018 · External reference
Challenges to HIV treatment adherence amongst adolescents in a low socio-economic setting in Cape Town.
10.4102/sajhivmed.v20i1.1002 · 2019 · External reference
Broadly Neutralizing Antibodies for HIV-1 Prevention
2021 · External reference
HIV therapy by a combination of broadly neutralizing antibodies in humanized mice
10.1038/nature11604 · 2012 · External reference
A Meta-analysis of Passive Immunization Studies Shows that Serum-Neutralizing Antibody Titer Associates with Protection against SHIV Challenge
10.1016/j.chom.2019.08.014 · 2019 · External reference
Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1
10.1056/nejmoa2031738 · 2021 · External reference
Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption
10.1056/nejmoa1608243 · 2016 · External reference
HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption
10.1038/nature18929 · 2016 · External reference
Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117
10.1038/nature14411 · 2015 · External reference
Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial
10.1038/s41591-022-01815-1 · 2022 · External reference
Antibody 10–1074 suppresses viremia in HIV-1-infected individuals
10.1038/nm.4268 · 2017 · External reference
Combination anti-HIV antibodies provide sustained virological suppression
10.1038/s41586-022-04797-9 · 2022 · External reference
Broadly neutralizing antibody treatment maintained HIV suppression in children with favorable reservoir characteristics in Botswana.
10.1126/scitranslmed.adh0004 · 2023 · External reference
Factors and Mechanisms for Pharmacokinetic Differences between Pediatric Population and Adults.
10.3390/pharmaceutics3010053 · 2011 · External reference
Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding
10.1126/science.1207227 · 2011 · External reference
Recombinant HIV envelope trimer selects for quaternary-dependent antibodies targeting the trimer apex
10.1073/pnas.1415789111 · 2014 · External reference
Broadly neutralizing HIV antibodies define a glycan-dependent epitope on the prefusion conformation of gp41 on cleaved envelope trimers
10.1016/j.immuni.2014.04.009 · 2014 · External reference
Systematic Assessment of Antiviral Potency, Breadth, and Synergy of Triple Broadly Neutralizing Antibody Combinations against Simian-Human Immunodeficiency Viruses
10.1128/jvi.01667-20 · 2021 · External reference
Sustained Delivery of a Broadly Neutralizing Antibody in Nonhuman Primates Confers Long-Term Protection against Simian/Human Immunodeficiency Virus Infection
10.1128/jvi.00210-15 · 2015 · External reference
Analytical Treatment Interruption after Short-Term Antiretroviral Therapy in a Postnatally Simian-Human Immunodeficiency Virus-Infected Infant Rhesus Macaque Model.
10.1128/mbio.01971-19 · 2019 · External reference
Simian-Human Immunodeficiency Virus SHIV.CH505 Infection of Rhesus Macaques Results in Persistent Viral Replication and Induces Intestinal Immunopathology
2019 · External reference
Neutralization titer biomarker for antibody-mediated prevention of HIV-1 acquisition
10.1038/s41591-022-01953-6 · 2022 · External reference
Global panel of HIV-1 Env reference strains for standardized assessments of vaccine-elicited neutralizing antibodies
10.1128/jvi.02853-13 · 2014 · External reference
Postnatally-transmitted HIV-1 Envelope variants have similar neutralization-sensitivity and function to that of nontransmitted breast milk variants.
10.1186/1742-4690-10-3 · 2013 · External reference
Safety, Tolerability, and Pharmacokinetics of a Long-Acting Broadly Neutralizing Human Immunodeficiency Virus Type 1 (HIV-1) Monoclonal Antibody VRC01LS in HIV-1-Exposed Newborn Infants.
10.1093/infdis/jiab229 · 2021 · External reference
Cost-effectiveness of broadly neutralizing antibody prophylaxis for HIV-exposed infants in sub-Saharan African settings
10.1002/jia2.26052 · 2023 · External reference
Single-dose bNAb cocktail or abbreviated ART post-exposure regimens achieve tight SHIV control without adaptive immunity
10.1038/s41467-019-13972-y · 2020 · External reference
Protective Efficacy of Broadly Neutralizing Antibodies with Incomplete Neutralization Activity against Simian-Human Immunodeficiency Virus in Rhesus Monkeys
10.1128/jvi.01187-17 · 2017 · External reference
Evaluating the Safety and Pharmacokinetics of VRC01, VRC01LS, and VRC07-523LS, Potent Anti-HIV Neutralizing Monoclonal Antibodies, in HIV-1-Exposed Infants NCT02256631
External reference
Safety, Tolerability, and Pharmacokinetics of the Broadly Neutralizing Human Immunodeficiency Virus (HIV)-1 Monoclonal Antibody VRC01 in HIV-Exposed Newborn Infants.
10.1093/infdis/jiz532 · 2019 · External reference
Paediatric pharmacokinetics: key considerations
10.1111/bcp.12267 · 2015 · External reference
Safety, pharmacokinetics, and immunogenicity of the combination of the broadly neutralizing anti-HIV-1 antibodies 3BNC117 and 10–1074 in healthy adults: A randomized, phase 1 study.
10.1371/journal.pone.0219142 · 2019 · External reference
Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques
10.1084/jem.20132494 · 2014 · External reference
Early short-term treatment with neutralizing human monoclonal antibodies halts SHIV infection in infant macaques
10.1038/nm.4063 · 2016 · External reference
Enhanced neonatal Fc receptor function improves protection against primate SHIV infection
10.1038/nature13612 · 2014 · External reference
Selection of HIV Envelope Strains for Standardized Assessments of Vaccine-Elicited Antibody-Dependent Cellular Cytotoxicity-Mediating Antibodies
10.1128/jvi.01643-21 · 2022 · External reference
Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults.
10.1371/journal.pmed.1002493 · 2018 · External reference
Simian-Human Immunodeficiency Virus SHIV.C.CH505 Persistence in ART-Suppressed Infant Macaques Is Characterized by Elevated SHIV RNA in the Gut and a High Abundance of Intact SHIV DNA in Naive CD4(+) T Cells.
10.1128/jvi.01669-20 · 2020 · External reference
Measuring HIV neutralization in a luciferase reporter gene assay
10.1007/978-1-59745-170-3_26 · 2009 · External reference
HIV-1 vaccine-induced C1 and V2 Env-specific antibodies synergize for increased antiviral activities
10.1128/jvi.00156-14 · 2014 · External reference
Replication competent molecular clones of HIV-1 expressing Renilla luciferase facilitate the analysis of antibody inhibition in PBMC
10.1016/j.virol.2010.08.028 · 2010 · External reference
Antibody-Mediated Internalization of Infectious HIV-1 Virions Differs among Antibody Isotypes and Subclasses.
10.1371/journal.ppat.1005817 · 2016 · External reference
Optimizing clinical dosing of combination broadly neutralizing antibodies for HIV prevention
10.1371/journal.pcbi.1010003 · 2022 · External reference
CATNAP: a tool to compile, analyze and tally neutralizing antibody panels
10.1093/nar/gkv404 · 2015 · External reference
